Replies to post #169915 on Anavex Life Sciences Corp (AVXL)

[Talon38]

Nidan....quite so. As Kitty Hawk showed the public and the US Army the possibilities of heavier-than-air machines, the results today of 2-73 when viewed by the experts in AD, will open eyes to the possibilities of effective treatment for the disease. Add to this, with the direct comparison to the two other leading candidates on the CTAD stage, BAN2401 and Aducanumab, we are several lengths ahead into the "final turn". IMHO, Tayo Fadiran has been working full time on the US AD trial and that most likely will be announced by the end of the year under the ACTC flag. Rationale: can anyone identify another candidate with the safety record, efficacy and precision data that 2-73 brings to the table. Additionally, The FDA must be aware of the broad application potential that 2-73 brings to treating CNS diseases. It will logically be Scott Gottlieb and Janet Woodcock's(and POTUS) poster child for what 21stCCA CNS drugs should be:

..........................................SAFE - EFFECTIVE - AFFORDABLE..........................................................

[McMagyar]

amen

[Jonjones325]

True. How do you sit back and do nothing while a company is doing everything you’ve been talking about?

And not give it the support it needs to be successful quicker. Now we are starting a 450 patient trial. SAME EXACT path as the traditional old school thought.

What are we getting for all of this innovation? Nothing. Where are the shorter timelines?

When does big data and small sample win?

FDA. Stop talking and act. You’ve got the perfect test case in front of you for whatever you want. With great chances of success.

I guess it’s possible the fda didn’t see this new data yet. Maybe it’s being prepared in an nice package to Gottlieb. And it says.

You’re welcome. From an old friend. Talk soon. Fadiran